Luokang Renaissance Biopharmaceutical Achieves Three Consecutive Years of Double-Digit Revenue and Profit Growth Driven by Innovation and High-Quality Expansion

Gelonghui March 20 — Today, Fosun Hanlin (2696.HK) released its 2025 annual results. During the reporting period, the company achieved revenue of 6.666 billion yuan, a year-on-year increase of 16.5%; net profit of 827 million yuan. The company’s full-year R&D investment reached 2.4919 billion yuan, a 35.4% increase year-on-year. Amid ongoing increased innovation investment, R&D expenses before profit reached 2.3425 billion yuan, up 26.2% year-on-year. This marks the company’s third consecutive year of both revenue and profit growth since its first full-year profit in 2023, demonstrating strong profitability resilience and high-quality growth capability.

In 2025, Fosun Hanlin’s global growth momentum continued to release, with global product revenue reaching 5.7746 billion yuan, a 17.0% increase year-on-year. As the company’s core products H药 Hansol® (Slerulizumab, European brand name: Hetronifly®) and Hanquyou® (Trastuzumab, US brand name: HERCESSI™, European brand name: Zercepac®) continue to grow overseas and the value of licensing collaborations accelerates, the company’s overseas revenue surged: overseas product revenue exceeded 200 million yuan, doubling from the previous year; overseas product profit reached 93.9 million yuan. As of now, the company has 10 products approved for launch in 60 countries and regions worldwide, including 7 approved in China, 4 approved by the US FDA, and 4 approved by the EU EC, benefiting over 1 million patients globally.